Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel

Anti-Cancer Drugs

Volumn 20, Issue 9, 2009, Pages 845-847

  Grenader, Tal ^a   Goldberg, Anthony ^a   Gabizon, Alberto ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

5 fluorouracil; Colorectal cancer; FOLFOX; Liver metastases; Oxaliplatin; Severe liver dysfunction

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL RADIOGRAPHY; ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 70349102075     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832fd779     Document Type: Article

References (6)

1. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology 2005; 19:1057-1063.
2. Ansfield FJ, Schroeder JM, Curreri AR. Five years clinical experience 5-florouracil. JAMA 1962; 187:295-299.
3. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, et al. Phase 1 and pharmacokinetic study of 24-h infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol 2003; 14:1142-1147.
4. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al.; National Cancer Institute Organ Dysfunction Working Group Study. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664-2672.
5. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al.; National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007; 13:3660-3666.
6. Fakih MG. 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67:222-224